SALT LAKE CITY, April 11, 2011 /PRNewswire/ -- TechniScan's (OTC BB: TSNI) novel breast ultrasound technology and clinical results will be featured at the American Institute of Ultrasound Medicine's annual conference in New York this week.
As part of an educational session on advanced breast ultrasound imaging, Michael Andre, Ph.D., director of an ongoing clinical study at the University of California, San Diego Moores Cancer Center that enlists TechniScan's automated Warm Bath Ultrasound (WBU) technology, will be leading the discussion and explaining the latest results of the WBU ultrasound system.
TechniScan's WBU system not only employs the well-known properties of reflection ultrasound but also maps the breast by sending transmission ultrasound waves through it, which significantly improves the clinical information and may allow a radiologist to determine whether a breast lesion is a cyst, a benign fibroademona or a malignancy – without a biopsy.
Two of the world's leading experts on transmission ultrasound and the mathematics of inverse scattering, James Wiskin, Ph.D., a TechniScan founder and adjunct professor at the University of Utah Department of Bioengineering, along with his colleague David Borup, Ph.D., are co-authors on the study. Wiskin will also be participating in the New York session.
"This conference is a great opportunity for other physicians and scientists to learn of the scientific and medical advances the TechniScan system demonstrates," said Andre.
The goal of the new technology is to improve breast imaging using a quick and practical approach for examining the entire breast in detail and looking inside the breast for abnormalities. The images are captured using a comfortable, radiation-free method as a woman lies prone on an examination table and ultrasound is directed, using warm water as a coupling medium, into the woman's breast tissue.
The UC San Diego Moores Cancer Center has scanned over 150 women in the two years of the study and will be sharing detailed comparisons of the WBU technology to sonography and MRI during the education session where results to date show very high correlation.
TechniScan, Inc. is a medical device company engaged in the development and commercialization of a non-invasive imaging tool designed to provide physicians with automated ultrasound images of the human breast. TechniScan's Warm Bath Ultrasound™ (WBU™) imaging device is limited by U.S. law to investigational use unless, and until, cleared by the FDA. For more information, please visit www.tsni.com.
Forward Looking Statements
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate, "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "potential," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of TechniScan, Inc. (the "company") to be materially different from those expressed or implied by such forward-looking statements. The company's future operating results are dependent upon many factors, including risk factors discussed in the company's periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov, including the company's Annual Report on Form 10-K filed on March 22, 2010. The company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.